Mitochondrial fission inhibitor for primary biliary cholangitis

Overview

This innovative solution involves a mitochondrial fission inhibitor aimed at treating Primary Biliary Cholangitis (PBC), a condition characterized by bile duct destruction and mitochondrial dysfunction. The inhibitor targets the interactions between dynamin-related protein 1 (Drp1) and Fission 1 (Fis1), which are crucial in regulating mitochondrial fission. By inhibiting excessive mitochondrial fission, the compound aims to reduce oxidative stress and neuronal damage, potentially ameliorating mitochondrial dysfunction and mitigating bile duct damage in PBC patients.

Technical specifications

• Mitochondrial Dynamics: The inhibitor modulates Drp1-Fis1 interactions to regulate mitochondrial fission and maintain mitochondrial morphology.
• Applications: Designed for use in hepatocytes and cholangiocytes of PBC patients, it can also be relevant for conditions with similar mitochondrial dysfunctions, such as Sjögren’s syndrome and systemic sclerosis.
• Mechanism of Action: The compound has shown efficacy in models of cardiovascular and sepsis-related conditions, suggesting its potential to restore mitochondrial function and reduce autoantibody-mediated damage.
• Assessment Methods: The efficacy is evaluated through mitochondrial imaging, viability, apoptosis assays, and measurement of mitochondrial function markers like ATP production and ROS levels.

Technology readiness level

This mitochondrial fission inhibitor is at Technology Readiness Level 5, indicating that it has been validated in relevant environments and is undergoing further validation in cell culture models to assess its impact on mitochondrial dynamics and autoantibody interactions in PBC.